Two of the biggest ASX success stories in recent years are WiseTech Global Ltd (ASX: WTC) and Pro Medicus Ltd (ASX: PME).
Investors who spotted their potential early and held on have been rewarded with extraordinary gains.
For example, WiseTech shares are up 275% over the past five years, whereas Pro Medicus shares are up 1,100% over the same period.
The challenge, of course, is how to identify the next generation of ASX winners before the rest of the market catches on. While there's no foolproof formula, there are some traits that these companies tend to share.
Look for global ambition
Both WiseTech and Pro Medicus didn't limit themselves to the Australian market. WiseTech has become a global logistics software leader, while Pro Medicus continues to win contracts with U.S. healthcare providers.
The next big winners are likely to be businesses with a product or service that can scale internationally. A small cap with an innovative solution but only local focus might not deliver the same outsized growth.
Recurring revenue is key
One of the secrets to compounding success is recurring revenue. WiseTech locks in customers with long-term software contracts, and Pro Medicus signs multi-year deals with major hospitals. That recurring revenue base makes earnings more predictable and allows reinvestment for further growth.
When assessing small caps, look for subscription models, long-term contracts, or mission-critical services that create sticky customer relationships.
Strong margins and capital-light models
Pro Medicus is famous for its extremely high profit margins, while WiseTech has steadily expanded its margins as it scales.
Both operate capital-light business models where growth doesn't require huge new factories or infrastructure. High margins and scalability often separate the next WiseTechs from the also-rans.
Early examples on the ASX
A few shares on the ASX today display some of these characteristics. Siteminder Ltd (ASX: SDR), for instance, provides a global hotel commerce platform with recurring subscription revenue and strong international growth prospects.
Objective Corporation Ltd (ASX: OCL) has been a quiet achiever, with sticky government and private sector software contracts driving compounding earnings.
And in healthcare, 4DMedical Ltd (ASX: 4DX) is pushing into the U.S. market with FDA-approved imaging technology that could one day replicate the Pro Medicus growth story — albeit still early in its commercialisation journey.
Foolish takeaway
Spotting the next WiseTech or Pro Medicus is never easy, and there will always be risks along the way. But by focusing on businesses with global ambition, recurring revenue, strong margins, and scalable models, investors give themselves the best chance of backing the next ASX superstar.
Patience is key. These shares don't become giants overnight — but for those willing to hold through the journey, the rewards can be spectacular.
